newsfilter
← Latest News
GlobeNewswire·

Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity in a heavily pretreated patient population Enrollme